Objective The preferred chemotherapy regimen for metastatic pancreatic cancer remains a matter of controversy. In the present study, we aimed to assess and rank the effectiveness and toxicity of all of the available chemotherapy regimens included in the last 15 years' randomized controlled trials (RCTs) for metastatic pancreatic adenocarcinomas objectively. Methods PubMed, Embase, Cochrane Collaboration database, and ClinicalTrials.gov were searched for RCTs comparing chemotherapy regimens as first-line treatment for metastatic pancreatic adenocarcinomas. Using a Bayesian network meta-analysis, we compared and ranked all included chemotherapy regimens in terms of the overall survival, progression-free survival, response rate, and hematological toxicity. Results We identified 2,206 articles and included in the analysis 46 eligible articles reporting 44 RCTs with a total of 9,133 patients and 48 first-line intravenous systemic chemotherapy regimens. The models showed a good fit to the data. The top-ranked chemotherapy regimen for the overall survival was FP (simplified leucovorin + fluorouracil + nab-paclitaxel), with a hazard ratio (HR) of 0.45 versus gemcitabine monotherapy (95% credible interval 0.28-0.71). The regimen ranked first for the progression-free survival was gemcitabine + erlotinib + bevacizumab (HR 0.39,. GS (gemcitabine + S-1) had the highest overall response rate [odds ratio (OR) versus gemcitabine monotherapy 7.06, 1.15-51.15]. GemCape (gemcitabine + capecitabine) + erlotinib was ranked the most hematologically toxic (OR 7.78,). Conclusion The available evidence suggests that FP ranked first for metastatic pancreatic cancer in terms of the overall survival. GemCape + erlotinib ranked the most toxic.
Introduction
Metastatic pancreatic adenocarcinomas account for about 52% pancreatic adenocarcinomas, with a 5-year overall survival rate around 3% (1) . The mainstream treatment for metastatic pancreatic adenocarcinoma is systemic chemother-Many randomized controlled trials (RCTs) have compared various of the chemotherapy regimens, providing important evidence, but many of the regimens have not been subjected to direct comparisons.
As a supplement, meta-analyses provide a method for summarizing available evidence, but traditional pairwise meta-analyses can be inefficient and unsuitable for summarizing and comparing different types of chemotherapy regimens simultaneously. In particular, traditional pairwise metaanalyses do not allow indirect comparisons in the absence of direct one-to-one comparisons, and they often compare only two arms.
Network meta-analyses offer a solution to these problems, making indirect comparison possible and allowing direct and indirect comparisons to be combined so that several treatments can be compared simultaneously (5) (6) (7) . Bayesian network meta-analyses are a special type of network metaanalysis, which making network meta-analysis has a wider range of applications (allowing for > 2 armed trials being included) and get a more precise stable outcome. In addition, Bayesian network meta-analysis can combine studies that report their outcomes using different measurement methods, avoiding potential publication bias (8) .
There have been two previous network meta-analyses that compared systemic regimens for locally advanced or metastatic pancreatic adenocarcinoma. The first only included 22 studies and compared 9 regimens, and it did not compare response rates (9) . A recently concluded network metaanalysis by Liu et al. compared 12 chemotherapy regimens for advanced or metastatic pancreatic cancer from 20 included studies (10) . These meta-analyses provided a summary of chemotherapy regimens to a certain extent. However, few meta-analyses have been specific to patients with metastatic adenocarcinoma, even though the prognosis for locally advanced and metastatic pancreatic adenocarcinoma differs significantly, with 5-year survival rates of 11% and 3%, respectively (1) . Thus far, no meta-analysis has provided a summary and rank of chemotherapy regimens for metastatic pancreatic cancer, covering all of the available studies for a sufficient period and relevant regimens and types of outcome.
In the present study, we performed a Bayesian network meta-analysis to analyze all of the relevant RCTs published in the last 15 years, comparing and ranking treatment regimens specific to metastatic pancreatic adenocarcinomas in terms of the overall survival, progression-free survival, overall response rate, disease control rate, and grade 3-4 hematological toxicity, to provide some objective clues or references for future research and clinical practice.
Method

Design
Our primary aim was to rank all of the included chemotherapy regimens in terms of the overall survival, progression-free survival, response rate, and grade 3-4 hematological toxicities using a Bayesian network metaanalysis.
Selection criteria
We only considered RCTs that included patients with metastatic pancreatic cancer and compared two or more chemotherapy regimens used as intravenous first-line treatment (or compared regimens with placebo). To make this report as inclusive as possible and to reduce publication bias, we also included RCTs for advanced pancreatic adenocarcinomas patients that reported detailed data for metastatic pancreatic adenocarcinomas in subgroup analyses. For these RCTs, data of only patients with metastatic diseases were extracted for this study. The trials had to involve the random assignment of patients and had to have been published in English. We excluded trials that studied the chemotherapy regimens as second-line treatments, or only contained a single arm.
Search strategy
We searched PubMed, Embase, and the Cochrane Collaboration database for RCTs published in English between January 1, 2002, and May 2, 2017 (our reason for including the RCTs published in the last 15 years is listed in Appendix 1 in the Supplement) of chemotherapy regimens for metastatic pancreatic adenocarcinomas as first-line treatment. We also searched ClinicalTrials.gov for RCTs that had been completed or were in progress, manually searched the reference lists of relevant articles or reviews, and searched the US Food and Drug Agency website for relevant reports for supplements. Appendix 1 in the Supplement lists the detailed search terms and results.
Data extraction, outcomes, and assessment for risk of bias
Two investigators screened all potential articles, reviewed the full manuscripts of the included studies, and independently extracted the data. The process allowed for any discrepancies (including some less serious disagreements such as basic information extracted and some more serious things such as hazard ratio or odds ratio extracted from a trial) to be solved by discussion, with a third investigator intervening if necessary. Appendix 2 in the Supplement lists the data collected from the articles. When there were several reports of the same RCT published at different times after the study, we gave precedence to the updated data.
The primary outcomes of the meta-analyses were the overall survival and progression-free survival after treatment with therapies for metastatic pancreatic carcinoma. When collecting the survival data, we preferentially chose hazard ratios (HRs) as the measurement method because these not only provide time-to-event information but also take censoring into account (8) . If the HRs and corresponding 95% confidence intervals (CIs) were not reported in an article, we calculated these from the survival curve using the method described by Tierney et al. (11) . When neither the HRs with 95% CIs nor the survival curve was reported in the article, we collected data on the median survival duration. The extraction methods for the secondary outcomes (response rates and hematological toxicity) are given in Appendix 2 in the Supplement.
Two investigators independently assessed the risk of bias for all of the included RCTs using the Cochrane Risk of Bias method (12) . Disagreement was resolved by discussion between the two investigators or by the intervention of a third investigator to reach a consensus.
Data synthesis and analyses
For the Bayesian analysis, we used both fixed-effects and random-effects models in the analysis of the overall survival and progression-free survival (a random-effects model was used in the main text due to the potential heterogeneity; fixed-effects model results are listed in the Supplement for reference). We combined the different measures (HRs and median survival durations) into a single WinBUGS model using the approach reported by Woods et al. (8) . For the meta-analyses of response rate and toxic effects, we used the WinBUGS model proposed by Chaimani, which provided more parameters for analyses and graphing (13) .
We also performed a traditional pairwise meta-analysis using a random-effects model. The HRs with corresponding 95% CIs were calculated for the primary outcomes, and ORs with 95% CIs for the secondary outcomes. Heterogeneities in each pairwise comparison were assessed with the I 2 statistic and P-value (14) . We assessed the inconsistency between the direct and indirect comparisons by comparing the results obtained from the Bayesian network metaanalysis with those from the traditional pairwise metaanalysis.
To ensure the comparability of all of the included studies, we included RCTs according to selection criteria strictly and assessed the heterogeneity. To assess the clinical heterogeneity, we compared the baseline characteristics of the subjects in the included RCTs. For the same pairwise comparisons, we detected I 2 to evaluate heterogeneity. To account for other heterogeneities that were difficult to detect, we used the random-effects model to obtain the primary outcomes in this study.
We assessed the convergence of the Bayesian model with trace plots and the Brooks-Gelman-Rubin statistic (15) . We evaluated each model by comparing the mean posterior deviance and the number of data points and compared the deviance information criterion (DIC) between the fixed-effects and random-effects models. We assessed the ranking probabilities of each regimen for different outcomes by evaluating the surface under the cumulative ranking curve (SU-CRA) (16) . We plotted a funnel plot for each outcome to detect any publication bias in the network metaanalysis (16) .
The traditional meta-analysis was performed using the Stata software program, ver. 13.1 (StataCorp LCC, College Station, TX, USA) and the software package "metan" (command used to download and install package: ssc install metan), and the Bayesian network meta-analysis was performed using WinBUGS version 1.4.3 (Imperial College and MRC, Cambridge, UK). Our network meta-analysis used non-informative uniform and normal prior distributions (5, 6) . Two Markov chains were run simultaneously with two sets of initial values, setting 5,000 iterations for burn-ins and 55,000 iterations for total updating, with a thinning interval of 25-50 for each chain. The detailed parameters set for each outcome are listed in Appendix 2 in the Supplement. We also used ITC 2.0 (Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada) to calculate the indirect HRs as a supplement for WinBUGS.
Results
Study characteristics
The search of online databases and other resources identified a total of 2,206 articles ( Fig. 1 and Appendix 1 in the Supplement). We excluded 2,025 articles after screening the title and abstracts. The full texts of the remaining 181 articles were assessed in detail, resulting in the final inclusion of 46 publications reporting 44 RCTs (Appendix 3 in the Supplement). These studies compared 48 chemotherapy regimens or placebo (Fig. 2 , Table 1, Table 2 , and Appendix 3 in the Supplement). The assessments of the risk of bias for each study are presented in Appendix 4 in the Supplement. Among the 44 RCTs, 20 were judged to have a high risk of bias in the blinding of participants and personnel.
The included studies comprised a total of 9,188 patients. The mean sample size was 208 (range 33-861), and 57.9% of all the participants were male. The minimum and maximum median ages of the included trials were 58.0 and 70.0 years, respectively (Table 1) .
Meta-analysis results
Appendix 3 in the Supplement lists all of the included studies. HRs for death were reported or could be calculated for 30 studies, and the median survival duration could be found in 4 further studies; thus, the Bayesian network metaanalysis for the overall survival included 34 studies (comparing 31 treatment regimens; Appendix 5 in the Supplement). Appendix 6 in the Supplement shows the detailed results of the meta-analysis for the overall survival using both fixed-effects and random-effects models, and Of the included studies, 23 reported information on the overall response of 24 regimens, and 21 reported informa- (Fig. 4 and Appendix 8 in the Supplement). Gemcitabine + simtuzumab was the lowest-ranked regimen for improving the overall response rate (OR 0.42, 0.11-1.69) and CO-101 the lowest-ranked for improving the disease control rate (OR 0.59, 0.18-1.92).
The toxicity meta-analysis included 20 studies that reported information about grade 3-4 hematological toxicity; these studies compared a total of 24 chemotherapy regimens (Appendix 5 in the Supplement). GemCape (gemcitabine + capecitabine) + erlotinib ranked the most toxic (most grade 3-4 hematological toxic effects) compared with gemcitabine (OR 7.78, 0.75-95.60), and gemcitabine + irinotecan ranked the least toxic (OR 0.17, 0.04-0.79) (Fig. 5 and Appendix 9 in the Supplement).
The ranking of chemotherapy regimens for each outcome is summarized in Appendix 10 in the Supplement. For the overall survival, the most efficacious chemotherapy regimen was FP, and the least efficacious was gemcitabine + rigosertib. For the progression-free survival, gemcitabine + erlotinib + bevacizumab was the top-ranked regimen. For the overall response rate, GS ranked the most grade 3-4 hematologically toxic, and gemcitabine + irinotecan ranked the least. Table 1 shows no significant heterology in terms of subjects' baseline characteristics. For several pairwise comparisons, the I 2 was greater than 50% (Appendix 11 in the Supplement); therefore, in the main test, we used random-effects models to obtain our results. The Markov chains were convergent for each model, and the models' fit to the data was relatively good. The results (ORs or HRs) from the traditional pairwise meta-analysis and pooled network metaanalysis were similar, demonstrating an acceptable level of consistency between the direct and indirect comparisons (Appendix 11 in the Supplement). In contrast, the mean posterior deviance of the model approximates the number of data points (Appendix 12 in the Supplement). Comparisonadjusted funnel plots of the network meta-analysis for each outcome revealed no publication bias (Appendix 13 in the Supplement).
Nine of the 44 studies were not included in any network meta-analysis (17-25). We summarized them in Appendix 
Discussion
Gemcitabine monotherapy has historically been used for decades as the standard first-line treatment for unresectable locally advanced or metastatic pancreatic cancer (26) . However, various new antitumor drugs or chemotherapy regimens have been subjected to clinical trials to improve the survival from metastatic pancreatic cancer. Using a Bayesian meta-analysis, the present study summarized and analyzed all of the available RCTs published in the last 15 years that compared chemotherapy regimens for metastatic pancreatic cancer. We ranked all of the available chemotherapy regimens in terms of their outcomes. This showed that several chemotherapy regimens resulted in a better overall survival and progression-free survival than gemcitabine monotherapy.
In our meta-analysis, five chemotherapy regimens had a high ranking and were deemed capable of imparting a better overall survival than gemcitabine, with the FP the regimen that performed best (HR 0.45). However, there was no direct comparison between FP and gemcitabine. An RCT comparing FP and GP (gemcitabine + nab-paclitaxel) for metastatic pancreatic cancer was reported by Bachet et al. in 2017 (27) . In this study, 114 patients were randomly assigned to the FP group (39 patients) and the GP group (75 patients). FP imparted a better median overall survival than GP (11.4 months and 9.2 months, respectively), with 56 (77%) of 73 patients in the FP group experiencing at least 1 grade 3-4 toxicity, compared with 33 (87%) of 38 patients in the GP group. Although this trial was multicenter, all of the centers were in France. A comparison between GP and gemcitabine was reported in another RCT (3, 4) , which included 861 patients randomly assigned to GP (431 patients) or gemcitabine (430). In the study's first report in 2013, the median overall survival was 8.5 and 6.7 months in the GP and gemcitabine groups, respectively (3); in an updated report in 2014, the median overall survival was 8.7 and 6.6 months, respectively (4).
FOLFIRINOX, gemcitabine + IMM-101, gemcitabine + erlotinib + bevacizumab, and gemcitabine + erlotinib also had a high ranking and showed a better overall survival than gemcitabine monotherapy, with the longest reported median survival times for these being 11.1 months (2), 7.0 months (28), 7.1 months (29), and 6.0-7.7 months (29-32), respectively. Conversely, gemcitabine + rigosertib ranked last and resulted in the lowest overall survival (HR 1.25), with a median survival time of 6.1 months.
Our meta-analysis for the progression-free survival showed that gemcitabine + erlotinib + bevacizumab ranked first in terms of the progression-free survival (HR 0. Table 2 . CrI: credible interval, OR: odds ratio 607 patients, with approximately half in each group. The gemcitabine + erlotinib + bevacizumab group showed a significantly longer median progression-free survival (4.6 months) than the gemcitabine + erlotinib group (3.6 months). However, when interpreting the progression-free survival rankings, it is important to note that only 22 of the 44 included studies reported the progression-free survival as an outcome.
In the present study, GS was shown to rank first in terms of the overall response rate (OR 7.06). Comparisons between GS and gemcitabine were reported in three RCTs (33) (34) (35) (36) . All of these enrolled advanced pancreatic cancer patients, but only one reported the overall response rate for metastatic pancreatic cancer patients (33) . This study included 112 advanced pancreatic cancer patients from 16 institutions, among which were 81 patients with metastatic pancreatic cancer. The overall response rate of GS was 30.0%, compared with 7.3% for gemcitabine (33) .
In the meta-analysis of disease control rate, four chemotherapy regimens had a high ranking and displayed a significant advantage compared to gemcitabine, with GemCape + erlotinib and gemcitabine + erlotinib + bevacizumab being ranked first and second (both ORs > 9). A comparison between GemCape + erlotinib and gemcitabine + erlotinib showed disease control rates of 69.1% and 58.9%, respectively (32) . Similarly, a comparison between gemcitabine + erlotinib + bevacizumab and gemcitabine + erlotinib showed disease control rates of 75.9% and 68.9%, respectively (29) . Thus, the disease control rates of both GemCape+erlotinib and gemcitabine + erlotinib+bevacizumab were higher than that of gemcitabine + erlotinib. Furthermore, a comparison between gemcitabine+erlotinib and gemcitabine monotherapy showed disease control rates of 70.0% for gemcitabine + erlotinib and 28.2% for gemcitabine (31) .
Our meta-analysis showed that GemCape + erlotinib ranked the most grade 3-4 hematologically toxic (OR 7.78), but the difference compared with gemcitabine was not significant. In a previous study, grade 3-4 neutropenia was more common with GemCape + erlotinib group than with gemcitabine + erlotinib (43% vs. 17%) (32) . Another RCT showed that grade 3-4 neutropenia was more frequent with gemcitabine + erlotinib than with gemcitabine alone (25.0% vs. 15.9%) (31) . The present study also showed that gemcitabine + irinotecan was associated with the lowest grade 3-4 hematological toxic effect (OR 0.17). A previous study showed that the hematological toxicity of gemcitabine + irinotecan was less than that of gemcitabine (41.6% vs. 82.8%) while its median overall survival was longer (7.1 vs. 6.4 months) (37) .
Our study had several strengths. First, to include as many trials as possible, we included not only the RCTs for metastatic pancreatic, but also those for advanced pancreatic can- Table 2 . CrI: credible interval, OR: odds ratio cer patients with a detailed subgroup analysis and data for metastatic cancer. For these RCTs, data of only patients with metastatic disease were extracted for this study. Second, we combined the outcomes obtained from different measurement methods (HRs and survival duration) into a single model, avoiding potential publication bias and the need for subgroup analysis (8) . Third, unlike traditional pairwise comparisons, the Bayesian network meta-analysis allowed us to make indirect comparisons (5-7). Fourth, this study evaluated all of the available RCTs and compared all of the chemotherapy regimens individually instead of dividing them into several large groups. Fifth, the meta-analysis assessed chemotherapy regimens in a relatively comprehensive way, with the assessed outcomes including the overall survival, progression-free survival, overall response rate, disease control rate, and grade 3-4 hematological toxicity. These comprehensive results can provide a degree of reference or clues for future clinical practice and research.
However, several limitations associated with the present study also warrant mention. First, our study only included RCTs published in the last 15 years; the reasons for this are listed in Appendix 1 in the Supplement. Second, there was a certain degree of heterogeneity. An attempt was made to control this heterogeneity. A random-effects model was used for the network analysis of primary outcomes in the main text. The results of a fixed-effects model are shown in the Appendix in the Supplement. The results of the randomeffects model were similar to those of the fixed-effects model, suggesting that the results were relatively stable and reliable. Third, there may be differences in the results of the network meta-analysis and those obtained in clinical practice. The data should be interpreted with care because they provide only an objective summary of the evidence. The chemotherapy regimen ranked first in the overall survival may not be the one most commonly used in clinical practice. Indeed, some chemotherapy regimens commonly used in the clinical setting were not found in this meta-analysis. To address this limitation, a similar Bayesian analysis of systemic chemotherapy for advanced pancreatic cancer was performed. Differences between the data obtained in this analysis and those obtained in clinical practice are an important topic for future study. Fourth, we were unable to summarize and compare non-hematological toxicity; the reasons for this are given in Appendix 2 in the Supplement. Fifth, we did not perform subgroup analyses or meta-regression. Subgroup meta-analyses and meta-regression are not possible without enough of the same one-to-one comparisons. However, most of the available one-to-one comparisons were only performed once, and most regimens were assessed in only a single RCT. Furthermore, any subgroup analysis might split the network. Sixth, we did not construct a contribution matrix or test local inconsistency. We included too many chemotherapy regimens and studies for this, making the test impractical. For example, the meta-analysis of the overall survival involved 31 chemotherapy regimens requiring 43 direct comparisons and 422 indirect comparisons, leading to 19,995 variables. In addition, most comparisons were made in only one study, and few loops were identified in the network plot, making the contribution matrix and test of local inconsistency less important. Finally, our meta-analysis used published data instead of individual patient data.
Despite these limitations, the study could still have useful implications for future research and clinical practice. First, the data in the current study provide a comprehensive summary, comparison, and ranking of efficacy and safety results extracted from RCTs evaluating chemotherapy regimens in the last 15 years. By referring to the data, we were able to easily determine the ranking position of a specific chemotherapy regimen and its effect on metastatic pancreatic cancer compared to gemcitabine. Second, by referring to the data provided here, we were able to identify RCTs comparing two or more regimens of interest and easily determine the HRs or ORs of achieving various outcomes. Third, although most results of the trials included in this study were negative, we still found several chemotherapy regimens that had advantages over gemcitabine and showed great application potential. Furthermore, even the negative results provided some degree of information. Fourth, we compiled a relatively comprehensive summary of previous RCTs, facilitating further studies, as future researchers will not need to search for these RCTs one by one.
Conclusions
In summary, our findings indicated that FP ranked the first among all chemotherapy regimens for the overall survival, and gemcitabine + erlotinib + bevacizumab ranked the first in terms of the progression-free survival. GS was shown to be associated with the highest overall response rate. GemCape + erlotinib was ranked the most hematologically toxic. However, we should interpret these results with particular caution.
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